58.92 USD
↗ 0.31 (0.53%)LIVE (AS OF 03:38 PM EDT)
Royalty Pharma plc Class A Ordinary Shares
RPRXNASDAQ • USD
Market: OPEN
Royalty Pharma plc Class A Ordinary Shares (RPRX) is currently trading at $58.92. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". Notable factors include a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Sep 11, 2026.
Open?$58.66
High?$61.51
Low?$58.51
Prev. Close?$58.61
Volume?1.9M
Avg. Volume?3.0M
VWAP?$59.10
Rel. Volume?0.63x
Bid / Ask
Bid?$58.96 × 300
Ask?$58.98 × 200
Spread?$0.02
Midpoint?$58.97
Valuation & Ratios
Market Cap?26.1B
Shares Out?445.3M
Float?435.9M
Float %?98.3%
P/E Ratio?32.02
P/B Ratio?3.82
EPS?$1.83
Dividend?2.85%
Ex-Dividend?N/A
News
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Themes
Employees
100
Market Cap
26.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2020-06-16
Address
110 EAST 59TH STREET
NEW YORK, NY 10022
Phone: (212) 883-0200
NEW YORK, NY 10022
Phone: (212) 883-0200
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?42
Momentum?73
Short Sent.?57
Piotroski F-Score?4/9Mixed
Altman Z-Score?2.18Grey
Confidence?76%Moderate
Short InterestHigh
Short % of Float?2.73%Low
Short Interest?11.9M
Days to Cover?5.1
Free Float435.9M
Avg Daily Volume2.4M
Settlement Date2026-08-31
Financial Health
Current Ratio?2.80Strong
Quick Ratio?2.80Strong
Cash Ratio?1.29Strong
Debt/Equity?1.33Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score50/100
P/E?32.0PRICEY▾
Peers100
S&P28
P/B?3.82FAIR▾
Peers100
S&P46
P/S?10.29HIGH▾
Peers100
S&P8
P/FCF?8.8CHEAP▾
Peers100
S&P91
EV/EBITDA?20.0HIGH▾
Peers100
S&P26
EV/Sales?13.55HIGH▾
Peers100
S&P5
Returns & Efficiency
ROE?11.9%FAIR▾
Peers50
S&P43
ROA?4.1%FAIR▾
Peers50
S&P37
Cash Flow & Enterprise
FCF?$3.0B
Enterprise Value?$34.4B
Fundamentals ratios updated end of day